Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Niagen Bioscience ( (NAGE) ) just unveiled an announcement.
On July 25, 2025, ChromaDex, Inc., a subsidiary of Niagen Bioscience, signed a Supply Agreement with W. R. Grace & Co.-Conn, effective April 1, 2025, for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL). The agreement, which runs until April 30, 2029, includes provisions for automatic renewal and requires ChromaDex to purchase a minimum quantity of NRCL annually. The agreement also outlines a potential future License Agreement for ChromaDex to manufacture NRCL, though its execution is not guaranteed.
The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
Niagen Bioscience’s strong financial performance and positive earnings call sentiment are major strengths, indicating robust growth and profitability. However, technical analysis reveals bearish momentum, and the high P/E ratio suggests potential overvaluation. These factors collectively result in a moderate overall stock score.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. operates in the bioscience industry, focusing on the production and supply of Nicotinamide-beta-Riboside Chloride (NRCL), a compound with potential health benefits.
Average Trading Volume: 1,099,087
Technical Sentiment Signal: Strong Buy
Current Market Cap: $763.3M
See more data about NAGE stock on TipRanks’ Stock Analysis page.